Related Experiment Video
Updated: Sep 10, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Durable response to a second course of immunotherapy in a long-term survivor with relapsed small cell lung cancer
Natalie Shammas1, Sajjad Bhatti2
1Internal Medicine, CHI Saint Vincent Health System, Little Rock, Arkansas, USA.
Abstract:
Chemoimmunotherapy (CIT) has significantly improved outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, relapses are common. Long-term survival (LTS) is possible for some patients with ES-SCLC treated with CIT regimens; however, the optimal duration for maintenance immunotherapy remains unknown. There is no data on optimal treatment options if LTS patients relapse while off therapy. Here, we are presenting a patient with ES-SCLC, who stopped treatment at 2 years, with disease relapse shortly afterwards. She was treated with a second course of single-agent immunotherapy with another durable remission.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy
Cells of the Adaptive Immune Response